Yongxiang C. Tang

No.87 Xiangya Road
Changsha, 410008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 91 publications

First-in-human evaluation of [18F]-AlF-NOTA-neurotensin for NTSR1-targeted imaging of prostate cancer: a head-to-head comparison with [68Ga]Ga-PSMA-617.

First-in-human evaluation of [18F]-AlF-NOTA-neurotensin for NTSR1-targeted imaging of prostate cancer: a head-to-head comparison with [68Ga]Ga-PSMA-617.

Journal: Annals of medicine

Published: June 17, 2026

Integrating PET and Fluorescence Imaging with a Novel PSMA-ICG Conjugate for Prostate Cancer Management.

Integrating PET and Fluorescence Imaging with a Novel PSMA-ICG Conjugate for Prostate Cancer Management.

Journal: Molecular pharmaceutics

Published: May 08, 2026

Cross-cohort projection of clinically anchored latent risk enables multi-omics interpretation without refitting.

Cross-cohort projection of clinically anchored latent risk enables multi-omics interpretation without refitting.

Journal: Briefings in bioinformatics

Published: April 07, 2026

PCO26-276: RET-Targeted Theranostics in Neuroendocrine Prostate Cancer: A Novel Molecular Target for Precision Imaging and Therapy.

PCO26-276: RET-Targeted Theranostics in Neuroendocrine Prostate Cancer: A Novel Molecular Target for Precision Imaging and Therapy.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 01, 2026

BPI26-007: Avoiding Unnecessary Biopsies for Non-Clinically Significant Prostate Cancer in Patients With PSA 4-20 ng/mL Using PRIMARY Score ≤3 and PSAD ≤0.2 ng/mL/cm³: A Real-World, Dual-Centre Study From China.

BPI26-007: Avoiding Unnecessary Biopsies for Non-Clinically Significant Prostate Cancer in Patients With PSA 4-20 ng/mL Using PRIMARY Score ≤3 and PSAD ≤0.2 ng/mL/cm³: A Real-World, Dual-Centre Study From China.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 31, 2026

Neuroimmune activation in temporal lobe epilepsy patients with worsening seizure following the COVID-19 pandemic: A [18F]DPA-714 PET/MR study.

Neuroimmune activation in temporal lobe epilepsy patients with worsening seizure following the COVID-19 pandemic: A [18F]DPA-714 PET/MR study.

Journal: Science advances

Published: January 30, 2026

Development and Evaluation of [68Ga]Ga-FAPI-A1 as a Novel Radiotracer Targeting Fibroblast Activation Protein.

Development and Evaluation of [68Ga]Ga-FAPI-A1 as a Novel Radiotracer Targeting Fibroblast Activation Protein.

Journal: Molecular pharmaceutics

Published: December 31, 2025

Reduced synaptic density in patients with progressive supranuclear palsy: An 18F-SynVest-1 PET study.

Reduced synaptic density in patients with progressive supranuclear palsy: An 18F-SynVest-1 PET study.

Journal: Parkinsonism & related disorders

Published: December 28, 2025

Non-invasive diagnosis strategy integrating PSMA PET/CT and mpMRI for patients with suspected prostate cancer: a multi-center study.

Non-invasive diagnosis strategy integrating PSMA PET/CT and mpMRI for patients with suspected prostate cancer: a multi-center study.

Journal: BMC medicine

Published: November 26, 2025

Beyond nigrostriatal dopamine transporter loss: whole-brain DAT depletion patterns discriminate PD phenotypes.

Beyond nigrostriatal dopamine transporter loss: whole-brain DAT depletion patterns discriminate PD phenotypes.

Journal: European journal of nuclear medicine and molecular imaging

Published: October 21, 2025

Head-to-Head Comparison of mpMRI, PSMA, GRPR PET/CT, and PET/CT Plus MRI for Local Staging of Primary Prostate Cancer and Their Prognostic Value.

Head-to-Head Comparison of mpMRI, PSMA, GRPR PET/CT, and PET/CT Plus MRI for Local Staging of Primary Prostate Cancer and Their Prognostic Value.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: October 03, 2025

Systemic brain-body metabolic coupling patterns in amyotrophic lateral sclerosis: a whole-body [18F] fluorodeoxyglucose PET/CT study across clinical phenotypes.

Systemic brain-body metabolic coupling patterns in amyotrophic lateral sclerosis: a whole-body [18F] fluorodeoxyglucose PET/CT study across clinical phenotypes.

Journal: European journal of nuclear medicine and molecular imaging

Published: September 26, 2025

Showing 1-12 of 91

Last Updated: 09/26/2026